johnson & johnson, page-33

You fail to understand what I mean. Look at the forest not the trees. I have been quite clear.

It is the interferon based regimes that are destined for the history books .

It is the twelve and six months courses that are destined for the history books.

BIT225 or a new stronger version could be an adjunct in a twelve week (or perhaps even eight) combo with a DAA. The issue for me there is that they have not taken that pathway yet and other drugs are doing that job already.
The soon to be approved Ledipasvir is my prime example. There are others coming through from Abbvie etc.

Price is an issue and I as I have said before, I can only guess that Biotron is planning on gaining market share because it may be be cheaper. The third world (and I include many poorer Asian countries) may not afford the shorter and more expensive regimes. As I said this is pure guesswork and does not require dissecting.